Curis (CRIS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 Jun, 2026Executive summary
A special meeting will be held virtually on June 25, 2026, to vote on a reverse stock split and a potential adjournment proposal.
The reverse stock split would combine issued shares at a ratio between 1-for-5 and 1-for-25, as determined by the board within six months of approval.
The primary goal is to increase the share price to meet Nasdaq listing requirements and avoid delisting.
The board recommends voting in favor of both proposals.
Voting matters and shareholder proposals
Proposal 1 seeks approval for amendments to effect a reverse stock split at a ratio between 1-for-5 and 1-for-25, with the board having discretion on timing and ratio.
Proposal 2 allows adjournment of the meeting to solicit more proxies if needed for Proposal 1.
Only these two proposals will be considered at the meeting; no other business will be transacted.
Each share entitles the holder to one vote; a majority of votes cast is required for approval.
Stockholder proposals for the 2027 annual meeting must be submitted by December 22, 2026, for inclusion in the proxy statement.
Board of directors and corporate governance
The board retains authority to abandon the reverse stock split even after stockholder approval if deemed not in the best interest of the company.
The board will determine the exact ratio and timing of the reverse split and will publicly announce the decision.
Latest events from Curis
- Emavusertib shows superior efficacy and safety in lymphoma and AML, with broad expansion plans.CRIS
Corporate presentation5 Jun 2026 - Shareholders to vote on a reverse stock split to help maintain Nasdaq listing compliance.CRIS
Proxy filing22 May 2026 - All five shareholder proposals, including director elections and share increase, were approved.CRIS
AGM 202619 May 2026 - Q1 2026 net loss was $24.2M; cash runway extends into H2 2027, but viability is uncertain.CRIS
Q1 202613 May 2026 - Shareholders will vote on director elections, executive pay, auditor ratification, and a share increase.CRIS
Proxy filing22 Apr 2026 - Shareholders will vote on director elections, executive pay, auditor ratification, and a major share increase.CRIS
Proxy filing10 Apr 2026 - Emavusertib delivers deep, durable responses in blood cancers and advances toward registrational trials.CRIS
Corporate presentation1 Apr 2026 - Q4 2025 net income surged on Erivedge sale; PCNSL and CLL studies drive future growth.CRIS
Q4 202520 Mar 2026 - Shareholders to vote on share increase, PIPE-related issuances, and a new equity incentive plan.CRIS
Proxy Filing19 Feb 2026